Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | CA3 | P07451 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 11/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL1679512 | 0.97 | CA12 (0.55) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL6880870 | 0.93 | CA12 (0.50) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL19371818 | 0.93 | CA12 (0.50) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL3487571 | 0.84 | CA12 (0.41) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL27681918 | 0.83 | CA12 (0.73) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL27965678 | 0.80 | CA12 (0.69) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL8375278 | 0.80 | CA12 (0.69) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL4294325 | 0.80 | CA12 (0.69) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL21753960 | 0.80 | CA12 (0.69) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL11227306 | 0.78 | CA12 (0.65) | CA12CA1CA2GLACA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20160304451-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-10-20 | — | — | US | disclosed |
| EP-1991574-B1 | OXYNTOMODULIN DERIVATIVES | MERCK SHARP & DOHME (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9408926-B2 | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy | BRACCO SUISSE S.A. (CH) | 2016-08-09 | — | — | US | disclosed |
| EP-2471811-B1 | Oxyntomodulin derivatives | MERCK SHARP & DOHME (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2802355-A1 | MUTANT ANTIBODIES AND CONJUGATION THEREOF | CovX Technologies Ireland Limited (IE) | 2014-11-19 | — | — | EP | disclosed |
| US-20140161732-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | BRACCO SUISSE S.A. (CH) | 2014-06-12 | — | — | US | disclosed |
| EP-2471811-A9 | Oxyntomodulin derivatives | Merck Sharp & Dohme Corp. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2013105013-A1 | MUTANT ANTIBODIES AND CONJUGATION THEREOF | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2013-07-18 | — | — | WO | disclosed |
| US-8268779-B2 | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition | MERCK SHARP & DOHME CORP. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2471811-A1 | Oxyntomodulin derivatives | Merck Sharp & Dohme Corporation (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471810-A1 | Oxyntomodulin derivatives | Merck Sharp & Dohme Corporation (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20110183902-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OXYNTOMODULIN DERIVATIVES AND A METHOD FOR REDUCING BODY WEIGHT USING THE COMPOSITION | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | US | disclosed |
| US-7928058-B2 | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition | MERCK SHARP & DOHME CORP. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100144617-A1 | Oxyntomodulin Derivatives | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| EP-1991574-A2 | OXYNTOMODULIN DERIVATIVES | Merck & Co., Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007100535-A2 | OXYNTOMODULIN DERIVATIVES | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144617-A1 | Oxyntomodulin Derivatives | GPR119, OGFRL1, OGFR | CA12 4453/4885CA1 4829/4885CA2 4734/4885 |
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA12 1100/4885CA1 1290/4885CA2 2352/4885 |
| US-20110183902-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OXYNTOMODULIN DERIVATIVES AND A METHOD FOR REDUCING BODY WEIGHT USING THE COMPOSITION | OGFR, GPR119, THOP1 | CA12 3827/4885CA1 4770/4885CA2 4548/4885 |
| US-20160304451-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA12 1100/4885CA1 1290/4885CA2 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.